Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination

Biomaterials

Volumn 150, Issue , 2018, Pages 162-170

  Uchida, Satoshi ^a,b   Yoshinaga, Naoto ^a,b   Yanagihara, Kayoko ^b,c   Yuba, Eiji ^d   Kataoka, Kazunori ^a,b   Itaka, Keiji ^b,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Osaka Prefecture University   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Double stranded RNA; Immunostimulatory adjuvant; Messenger RNA vaccine; Pattern recognition receptor

Indexed keywords

ANTIGENS; CHEMICAL ACTIVATION; EFFICIENCY; IMMUNE SYSTEM; MAMMALS; PATTERN RECOGNITION; RNA; VACCINES;

ANTIGEN PRESENTING CELLS; DOUBLE-STRANDED RNA; HUMAN DENDRITIC CELLS; HUMORAL IMMUNE RESPONSE; IMMUNOSTIMULATORY ADJUVANT; MESSENGER RNA; PATTERN RECOGNITION RECEPTORS; TRANSLATIONAL EFFICIENCIES;

NUCLEIC ACIDS;

COMPLEMENTARY RNA; DOUBLE STRANDED RNA; MESSENGER RNA; POLYADENYLIC ACID; POLYURIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 3; ANTIGEN; ANTISENSE OLIGONUCLEOTIDE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA HYBRIDIZATION; RNA IMMUNIZATION; RNA TRANSLATION; SEQUENCE ANALYSIS; VACCINE IMMUNOGENICITY; ANIMAL; ANIMAL MODEL; C57BL MOUSE; CELL LINE; CHEMISTRY; GENETICS; HEK293 CELL LINE; IMMUNIZATION; IMMUNOLOGY; NUCLEIC ACID HYBRIDIZATION; PRIMARY CELL CULTURE; PROCEDURES; PROTEIN SYNTHESIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CELL LINE; DENDRITIC CELLS; HEK293 CELLS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NUCLEIC ACID HYBRIDIZATION; OLIGORIBONUCLEOTIDES, ANTISENSE; POLY A; POLY U; PRIMARY CELL CULTURE; PROTEIN BIOSYNTHESIS; RNA, DOUBLE-STRANDED; RNA, MESSENGER; VACCINES, DNA;

EID: 85030836923     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2017.09.033     Document Type: Article

References (44)

1. Kutzler, M.A., Weiner, D.B., DNA vaccines: ready for prime time?. Nat. Rev. Genet. 9:10 (2008), 776–788.
2. Dowd, K.A., Ko, S.Y., Morabito, K.M., Yang, E.S., Pelc, R.S., DeMaso, C.R., Castilho, L.R., Abbink, P., Boyd, M., Nityanandam, R., Gordon, D.N., Gallagher, J.R., Chen, X., Todd, J.P., Tsybovsky, Y., Harris, A., Huang, Y.S., Higgs, S., Vanlandingham, D.L., Andersen, H., Lewis, M.G., De La Barrera, R., Eckels, K.H., Jarman, R.G., Nason, M.C., Barouch, D.H., Roederer, M., Kong, W.P., Mascola, J.R., Pierson, T.C., Graham, B.S., Rapid development of a DNA vaccine for Zika virus. Science 354:6309 (2016), 237–240.
3. Kreiter, S., Diken, M., Selmi, A., Tureci, O., Sahin, U., Tumor vaccination using messenger RNA: prospects of a future therapy. Curr. Opin. Immunol. 23:3 (2011), 399–406.
4. Geall, A.J., Mandl, C.W., Ulmer, J.B., RNA: the new revolution in nucleic acid vaccines. Seminars Immunol. 25:2 (2013), 152–159.
5. Pollard, C., De Koker, S., Saelens, X., Vanham, G., Grooten, J., Challenges and advances towards the rational design of mRNA vaccines. Trends Mol. Med. 19:12 (2013), 705–713.
6. Sahin, U., Kariko, K., Tureci, O., mRNA-based therapeutics - developing a new class of drugs. Nat. Rev. Drug Discov. 13:10 (2014), 759–780.
7. Reed, S.G., Orr, M.T., Fox, C.B., Key roles of adjuvants in modern vaccines. Nat. Med. 19:12 (2013), 1597–1608.
8. Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S., Reis e Sousa, C., Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:5663 (2004), 1529–1531.
9. Kariko, K., Ni, H., Capodici, J., Lamphier, M., Weissman, D., mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279:13 (2004), 12542–12550.
10. Van Meirvenne, S., Straetman, L., Heirman, C., Dullaers, M., De Greef, C., Van Tendeloo, V., Thielemans, K., Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther. 9:9 (2002), 787–797.
11. Fotin-Mleczek, M., Duchardt, K.M., Lorenz, C., Pfeiffer, R., Ojkic-Zrna, S., Probst, J., Kallen, K.J., Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34:1 (2011), 1–15.
12. Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T.K., Pawelec, G., Hoerr, I., Rammensee, H.G., Garbe, C., Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32:5 (2009), 498–507.
13. Phua, K.K., Staats, H.F., Leong, K.W., Nair, S.K., Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci. Rep., 4, 2014, 5128.
14. Kranz, L.M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K.C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., Grunwitz, C., Vormehr, M., Husemann, Y., Selmi, A., Kuhn, A.N., Buck, J., Derhovanessian, E., Rae, R., Attig, S., Diekmann, J., Jabulowsky, R.A., Heesch, S., Hassel, J., Langguth, P., Grabbe, S., Huber, C., Tureci, O., Sahin, U., Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534:7607 (2016), 396–401.
15. Kuai, R., Ochyl, L.J., Bahjat, K.S., Schwendeman, A., Moon, J.J., Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater 16:4 (2017), 489–496.
16. Rittig, S.M., Haentschel, M., Weimer, K.J., Heine, A., Muller, M.R., Brugger, W., Horger, M.S., Maksimovic, O., Stenzl, A., Hoerr, I., Rammensee, H.G., Holderried, T.A., Kanz, L., Pascolo, S., Brossart, P., Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol. Ther. 19:5 (2011), 990–999.
17. Kubler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., Vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., Jocham, D., Maurer, T., Rippin, G., Fotin-Mleczek, M., von der Mulbe, F., Probst, J., Hoerr, I., Kallen, K.J., Lander, T., Stenzl, A., Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J. Immunother. Cancer, 3, 2015, 26.
18. Alexopoulou, L., Holt, A.C., Medzhitov, R., Flavell, R.A., Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:6857 (2001), 732–738.
19. Kato, H., Takeuchi, O., Mikamo-Satoh, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A., Dermody, T.S., Fujita, T., Akira, S., Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205:7 (2008), 1601–1610.
20. Schlee, M., Roth, A., Hornung, V., Hagmann, C.A., Wimmenauer, V., Barchet, W., Coch, C., Janke, M., Mihailovic, A., Wardle, G., Juranek, S., Kato, H., Kawai, T., Poeck, H., Fitzgerald, K.A., Takeuchi, O., Akira, S., Tuschl, T., Latz, E., Ludwig, J., Hartmann, G., Recognition of 5’ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31:1 (2009), 25–34.
21. Barbalat, R., Ewald, S.E., Mouchess, M.L., Barton, G.M., Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29 (2011), 185–214.
22. Ding, Y., Tang, Y., Kwok, C.K., Zhang, Y., Bevilacqua, P.C., Assmann, S.M., In vivo genome-wide profiling of RNA secondary structure reveals novel regulatory features. Nature 505:7485 (2014), 696–700.
23. Rouskin, S., Zubradt, M., Washietl, S., Kellis, M., Weissman, J.S., Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo. Nature 505:7485 (2014), 701–705.
24. Binder, M., Eberle, F., Seitz, S., Mucke, N., Huber, C.M., Kiani, N., Kaderali, L., Lohmann, V., Dalpke, A., Bartenschlager, R., Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J. Biol. Chem. 286:31 (2011), 27278–27287.
25. Leonard, J.N., Ghirlando, R., Askins, J., Bell, J.K., Margulies, D.H., Davies, D.R., Segal, D.M., The TLR3 signaling complex forms by cooperative receptor dimerization. Proc. Natl. Acad. Sci. U. S. A. 105:1 (2008), 258–263.
26. Botos, I., Liu, L., Wang, Y., Segal, D.M., Davies, D.R., The toll-like receptor 3:dsRNA signaling complex. Biochim. Biophys. Acta 1789:9–10 (2009), 667–674.
27. Spitale, R.C., Flynn, R.A., Zhang, Q.C., Crisalli, P., Lee, B., Jung, J.W., Kuchelmeister, H.Y., Batista, P.J., Torre, E.A., Kool, E.T., Chang, H.Y., Structural imprints in vivo decode RNA regulatory mechanisms. Nature 519:7544 (2015), 486–490.
28. Matsui, A., Uchida, S., Ishii, T., Itaka, K., Kataoka, K., Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases. Sci. Rep., 5, 2015, 15810.
29. Yang, J., Sanderson, N.S., Wawrowsky, K., Puntel, M., Castro, M.G., Lowenstein, P.R., Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. Proc. Natl. Acad. Sci. U. S. A. 107:10 (2010), 4716–4721.
30. Lutz, M.B., Kukutsch, N., Ogilvie, A.L., Rossner, S., Koch, F., Romani, N., Schuler, G., An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:1 (1999), 77–92.
31. Caskey, M., Lefebvre, F., Filali-Mouhim, A., Cameron, M.J., Goulet, J.P., Haddad, E.K., Breton, G., Trumpfheller, C., Pollak, S., Shimeliovich, I., Duque-Alarcon, A., Pan, L., Nelkenbaum, A., Salazar, A.M., Schlesinger, S.J., Steinman, R.M., Sekaly, R.P., Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 208:12 (2011), 2357–2366.
32. Worbs, T., Hammerschmidt, S.I., Forster, R., Dendritic cell migration in health and disease. Nat. Rev. Immunol. 17:1 (2017), 30–48.
33. Kariko, K., Buckstein, M., Ni, H., Weissman, D., Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:2 (2005), 165–175.
34. Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.K., Schlee, M., Endres, S., Hartmann, G., 5’-Triphosphate RNA is the ligand for RIG-I. Science 314:5801 (2006), 994–997.
35. Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C.M., Huber, C., Tureci, O., Sahin, U., Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70:22 (2010), 9031–9040.
36. Wang, Y., Ludwig, J., Schuberth, C., Goldeck, M., Schlee, M., Li, H., Juranek, S., Sheng, G., Micura, R., Tuschl, T., Hartmann, G., Patel, D.J., Structural and functional insights into 5’-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat. Struct. Mol. Biol. 17:7 (2010), 781–787.
37. Cazenave, C., Uhlenbeck, O.C., RNA template-directed RNA synthesis by T7 RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 91:15 (1994), 6972–6976.
38. Triana-Alonso, F.J., Dabrowski, M., Wadzack, J., Nierhaus, K.H., Self-coded 3’-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase. J. Biol. Chem. 270:11 (1995), 6298–6307.
39. Kolakofsky, D., Kowalinski, E., Cusack, S., A structure-based model of RIG-I activation. RNA 18:12 (2012), 2118–2127.
40. Schlee, M., Master sensors of pathogenic RNA - RIG-I like receptors. Immunobiology 218:11 (2013), 1322–1335.
41. Fotin-Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K.M., Kallen, K.J., Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J. Gene Med. 14:6 (2012), 428–439.
42. Van Lint, S., Goyvaerts, C., Maenhout, S., Goethals, L., Disy, A., Benteyn, D., Pen, J., Bonehill, A., Heirman, C., Breckpot, K., Thielemans, K., Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 72:7 (2012), 1661–1671.
43. Dewitte, H., Van Lint, S., Heirman, C., Thielemans, K., De Smedt, S.C., Breckpot, K., Lentacker, I., The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy. J. Control Release 194 (2014), 28–36.
44. Steeghs, L., Keestra, A.M., van Mourik, A., Uronen-Hansson, H., van der Ley, P., Callard, R., Klein, N., van Putten, J.P., Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis. Infect. Immun. 76:8 (2008), 3801–3807.